Plasma ctDNA monitoring during epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor treatment in patients with EGFR-mutant non-small cell lung cancer (JP-CLEAR trial)
Sign Up to like & getrecommendations! Published in 2019 at "Japanese Journal of Clinical Oncology"
DOI: 10.1093/jjco/hyz023
Abstract: ctDNA monitoring during EGFR-TKI treatment is useful for detecting T790M mutation. However, the efficacy of osimertinib treatment based on T790M status in plasma ctDNA remains to be established. read more here.
Keywords: ctdna; plasma ctdna; ctdna monitoring; treatment ... See more keywords